Aeterna Zentaris to Announce Second Quarter 2018 Financial and Operating Results on August 9, 2018
CHARLESTON, S.C., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) will announce its second quarter 2018 financial and operating results after market close on Thursday, August 9, 2018. The Company will host a conference call to discuss these results on Friday, August 10, 2018 at 8:30 a.m. Eastern Time.
Participants may access the conference call by telephone using the following numbers:
Toll-Free: 877-407-8029, Confirmation #13681858
Toll: 201-689-8029, Confirmation #13681858
A replay will also be available on the Company's website for a period of 30 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilentm (macimorelin), an oral ghrelin receptor agonist, to be administered in the diagnosis of patients with adult growth hormone deficiency. Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilentm (macimorelin) in the United States and Canada. For more information, visit www.zentaris.com.
Contact:
Aeterna Zentaris Inc. James Clavijo Chief Financial Officer [email protected] 843-900-3201
The Honourable Jean-Yves Duclos, MP for Québec and Minister of Public Services and Procurement, on behalf of the Honourable Mark Holland, Minister of Health, and the Honourable Carla Qualtrough, Minister of Sport and Physical Activity, will announce...
Chemistree Technology Inc. and (the "Company" or "Chemistree"), announces that is has completed the previously announced restructuring transaction (the "Restructuring Transaction") to settle $6,668,000 in principal amount of outstanding 10% senior...
Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provided an...
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:
On Thursday, the FDA provided information on how to safely charge hearing aids, glucose monitors, insulin pumps, and other medical...
JanOne Inc. announced today that it has executed a Definitive Agreement to acquire blockchain financial technology provider, ALT 5 Sigma Inc., a Delaware corporation, and each of its wholly-owned subsidiaries. The transaction is anticipated to close...
Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented data on its X-Editor (XE) and Epigenetic Long-Term X-Repressor (ELXR) technologies at the 27th American Society of...
